Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
18 authors.
Josephine K DermawanDepartment of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0002-1139-2914
Fabio VanoliDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Henry de Traux de WardinDepartment of Pediatrics, Brussels University Hospital, Academic Children's Hospital Queen Fabiola, Université Libre de Bruxelles, Brussels, Belgium.ORCID 0009-0000-0615-8982
Jonathan N LeviDepartment of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Glorymar Ibanez SanchezDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-8684-4148
Armaan SiddiqueeDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Samantha BrosiusDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0009-0004-7215-6343
Daoqi YouDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-4363-5893
Franck TirodeCancer Research Center of Lyon, CNRS 5286, INSERM U1052, Department of Biopathology, Centre Léon Bérard, Université Claude Bernard Lyon 1, Lyon, France.ORCID 0000-0003-4731-7817
Patricia SungDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0009-0004-9498-8896
Marie KaranianCancer Research Center of Lyon, CNRS 5286, INSERM U1052, Department of Biopathology, Centre Léon Bérard, Université Claude Bernard Lyon 1, Lyon, France.
Daniel PissalouxCancer Research Center of Lyon, CNRS 5286, INSERM U1052, Department of Biopathology, Centre Léon Bérard, Université Claude Bernard Lyon 1, Lyon, France.ORCID 0000-0003-1118-950X
Leonard H WexlerDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-0724-8263
Andrew KungDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-9091-488X
Alice SoragniDepartment of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.ORCID 0000-0002-6634-2885
Filemon S Dela CruzDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-8356-5191
Jovana PavisicDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-6968-600X
Cristina R AntonescuDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-9717-8205
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Targeting Oncogenic Pathways in Genetically Complex SarcomasP50CA217694 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Marc Ladanyi · 2018 to 2026
$21.5M
PROJECT 3: Applying Liquid Biopsy Technologies to Detect Clinical Response and Mechanisms of Resistance in the Treatment of LMSP50CA272170 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Elizabeth Demicco · 2022 to 2026
$13.3M
The Evolution of Sarcoma Drug Sensitivity through Time and SpaceR01CA244729 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BOUTROS, PAUL CHRISTOPHER, SORAGNI, ALICE · 2020 to 2024
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Single-cell protein activity analysis reveals aberrant myogenesis and IGF2-PI3K pathway dependencies in · full record | OpenQuestion